C. Louwrens Braal, Elisabeth M. Jongbloed, Saskia M. Wilting, Ron H. J. Mathijssen, Stijn L. W. Koolen, Agnes Jager
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs
that interrupt proliferation of malignant cells by inhibiting progression
through the cell cycle. Three such inhibitors, palbociclib, ribociclib, and
abemaciclib were recently approved for breast cancer treatment in various
settings and combination regimens. On the basis of their impressive efficacy,
all three CDK4/6 i... hiện toàn bộ